International Journal of Gynecological Cancer

Ovarian cancer in the proteomics era
pp. 1-6(6)
Authors: ANNUNZIATA,; AZAD,; DHAMOON,; WHITELEY,; KOHN,

Management of retroperitoneal lymph nodes in advanced ovarian cancer
pp. 7-10(4)
Authors: HACKER,; VALMADRE,; ROBERTSON,

Timing of debulking surgery in advanced ovarian cancer
pp. 11-19(9)
Authors: VERGOTE,; van GORP, T.; AMANT,; LEUNEN,; NEVEN,; BERTELOOT,

Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer
pp. 20-25(6)
Author: HOWELL,

National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer
pp. 26-28(3)
Authors: TRIMBLE,; CHRISTIAN,

Can carboplatin replace cisplatin for intraperitoneal use?
pp. 29-32(4)
Author: FUJIWARA,

Strategies to examine new compounds for intraperitoneal use in ovarian cancer
pp. 33-35(3)
Author: MARKMAN,

What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
pp. 36-39(4)
Author: MARKMAN,

Maintenance chemotherapy in advanced ovarian cancer: the US experience
pp. 40-43(4)
Author: MARKMAN,

Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer
pp. 44-46(3)
Authors: AURANEN,; GRÉNMAN,

First-line randomized trials: revisiting the Ptolemaic universe
pp. 47-52(6)
Author: BOOKMAN,

Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer
pp. 53-58(6)
Author: LEDERMANN,

Second-line randomized trials in epithelial ovarian cancer
pp. 59-66(8)
Author: VERMORKEN,

Ten years of “Optimal Therapy in Advanced Ovarian Cancer. Update” Meeting
pp. 67-70(4)
Author: POVEDA,

Future opportunities of the Gynecological Cancer Intergroup
pp. 71-73(3)
Author: STUART,

Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting
pp. 74-75(2)
Author: EISENHAUER,